Search
Login
Register
Menu
Last issue
Home
News
CongressUpdate
Guidelines
Specials
Links
All
All
BJH articles
Blog articles
Specials
Search
Forgot Password?
Not a member yet? Register here
News
>
Pharma News
>
New haematology reimbursement in Belgium: polatuzumab vedotin▼ (Polivy®) for previously untreated DLBCL
New haematology reimbursement in Belgium: polatuzumab vedotin▼ (Polivy®) for previously untreated DLBCL
January 2024
Pharma News
Jolien Blokken
(sponsored)
To view this article please log in on top of screen and belong to the target group of this article
.
Share this article
Share
Tweet
Share
Email
Share
Top
